NZ606042A - Process for the preparation of erlotinib and salts thereof - Google Patents
Process for the preparation of erlotinib and salts thereofInfo
- Publication number
- NZ606042A NZ606042A NZ606042A NZ60604211A NZ606042A NZ 606042 A NZ606042 A NZ 606042A NZ 606042 A NZ606042 A NZ 606042A NZ 60604211 A NZ60604211 A NZ 60604211A NZ 606042 A NZ606042 A NZ 606042A
- Authority
- NZ
- New Zealand
- Prior art keywords
- erlotinib
- preparation
- salt
- disclosed
- base
- Prior art date
Links
- 239000005551 L01XE03 - Erlotinib Substances 0.000 title abstract 4
- 229960001433 erlotinib Drugs 0.000 title abstract 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- NNKQLUVBPJEUOR-UHFFFAOYSA-N 3-ethynylaniline Chemical compound NC1=CC=CC(C#C)=C1 NNKQLUVBPJEUOR-UHFFFAOYSA-N 0.000 abstract 1
- ZPJLDMNVDPGZIU-UHFFFAOYSA-N 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline Chemical compound C1=NC(Cl)=C2C=C(OCCOC)C(OCCOC)=CC2=N1 ZPJLDMNVDPGZIU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 abstract 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ628796A NZ628796A (en) | 2010-07-23 | 2011-07-22 | Pure erlotinib |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2112MU2010 | 2010-07-23 | ||
| PCT/GB2011/051394 WO2012028861A1 (en) | 2010-07-23 | 2011-07-22 | Pure erlotinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ606042A true NZ606042A (en) | 2015-05-29 |
Family
ID=44514823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ606042A NZ606042A (en) | 2010-07-23 | 2011-07-22 | Process for the preparation of erlotinib and salts thereof |
| NZ628796A NZ628796A (en) | 2010-07-23 | 2011-07-22 | Pure erlotinib |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ628796A NZ628796A (en) | 2010-07-23 | 2011-07-22 | Pure erlotinib |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8952022B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2595629A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5948597B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103124557A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011298167B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2806273A1 (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ606042A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012028861A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2595629A1 (en) | 2010-07-23 | 2013-05-29 | Generics [UK] Limited | Pure erlotinib |
| CN103420924B (zh) * | 2012-05-25 | 2016-08-31 | 浙江九洲药业股份有限公司 | 一种盐酸埃罗替尼晶型a的制备方法 |
| WO2014023027A1 (zh) * | 2012-08-10 | 2014-02-13 | 上海创诺医药集团有限公司 | 盐酸埃罗替尼多晶型物及其制备方法 |
| WO2014118112A1 (en) * | 2013-01-29 | 2014-08-07 | Synthon B.V. | Pharmaceutical composition comprising erlotinib hydrochloride |
| WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
| CN104072427B (zh) * | 2013-03-29 | 2019-05-28 | 江苏豪森药业集团有限公司 | 盐酸厄洛替尼晶型的制备方法 |
| WO2020165672A1 (en) | 2019-02-15 | 2020-08-20 | Shivalik Rasayan Limited | Process for preparation of highly pure fingolimod hydrochloride |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69536015D1 (de) * | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7148231B2 (en) | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
| US7625911B2 (en) | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| WO2007060691A2 (en) * | 2005-11-23 | 2007-05-31 | Natco Pharma Limited | A novel process for the preparation of erlotinib |
| US8372856B2 (en) | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
| ES2573931T3 (es) | 2007-02-21 | 2016-06-13 | Natco Pharma Limited | Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación |
| CA2682013C (en) | 2007-04-04 | 2015-06-30 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
| US20090012295A1 (en) | 2007-06-25 | 2009-01-08 | Ales Gavenda | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib |
| ES2492645T3 (es) * | 2007-07-11 | 2014-09-10 | Hetero Drugs Limited | Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib |
| EP2218713A1 (en) * | 2007-08-17 | 2010-08-18 | Hetero Drugs Limited | Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B |
| US20090124642A1 (en) * | 2007-08-23 | 2009-05-14 | Augusto Canavesi | Crystalline forms of Erlotinib HCI and formulations thereof |
| TW200925151A (en) * | 2007-08-23 | 2009-06-16 | Plus Chemicals S A | Stable formulations of crystalline erlotinib HCL |
| US20100004449A1 (en) * | 2008-07-07 | 2010-01-07 | Plus Chemicals Sa | Crystalline forms of erlotinib base and erlotinib hcl |
| WO2010040212A1 (en) | 2008-10-08 | 2010-04-15 | Apotex Pharmachem Inc. | Processes for the preparation of erlotinib hydrochloride |
| EP2595629A1 (en) | 2010-07-23 | 2013-05-29 | Generics [UK] Limited | Pure erlotinib |
-
2011
- 2011-07-22 EP EP11741276.7A patent/EP2595629A1/en not_active Withdrawn
- 2011-07-22 AU AU2011298167A patent/AU2011298167B2/en not_active Ceased
- 2011-07-22 NZ NZ606042A patent/NZ606042A/en not_active IP Right Cessation
- 2011-07-22 WO PCT/GB2011/051394 patent/WO2012028861A1/en not_active Ceased
- 2011-07-22 NZ NZ628796A patent/NZ628796A/en not_active IP Right Cessation
- 2011-07-22 JP JP2013520221A patent/JP5948597B2/ja not_active Expired - Fee Related
- 2011-07-22 US US13/811,628 patent/US8952022B2/en active Active
- 2011-07-22 CN CN2011800459093A patent/CN103124557A/zh active Pending
- 2011-07-22 CA CA 2806273 patent/CA2806273A1/en not_active Abandoned
-
2015
- 2015-01-06 US US14/590,519 patent/US9340515B2/en active Active
-
2016
- 2016-05-06 JP JP2016093409A patent/JP6374436B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011298167A8 (en) | 2013-02-21 |
| CN103124557A (zh) | 2013-05-29 |
| CA2806273A1 (en) | 2012-03-08 |
| AU2011298167B2 (en) | 2015-11-26 |
| US9340515B2 (en) | 2016-05-17 |
| JP2016196463A (ja) | 2016-11-24 |
| WO2012028861A1 (en) | 2012-03-08 |
| NZ628796A (en) | 2016-02-26 |
| US20130210842A1 (en) | 2013-08-15 |
| AU2011298167A1 (en) | 2013-02-07 |
| JP5948597B2 (ja) | 2016-07-06 |
| JP6374436B2 (ja) | 2018-08-15 |
| US8952022B2 (en) | 2015-02-10 |
| EP2595629A1 (en) | 2013-05-29 |
| US20150111847A1 (en) | 2015-04-23 |
| JP2013531058A (ja) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ606042A (en) | Process for the preparation of erlotinib and salts thereof | |
| TW200600097A (en) | Stable crystal of 4-oxoquinoline compound technical field of the invention | |
| DK2057126T3 (da) | Fremgangsmåde til fremstilling af 3-dihalomethyl-pyrazol-4-carboxylsyrederivater | |
| NZ598277A (en) | Process for preparing azabicyclic compounds | |
| NZ599306A (en) | Process for the preparation of compounds useful as inhibitors of sglt2 | |
| AU2015221439B2 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same | |
| TN2011000326A1 (en) | Quinazolinone derivatives useful as vanilloid antagonits | |
| NZ624315A (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof. | |
| WO2012092471A3 (en) | Novel tubulin inhibitors and methods of using the same | |
| MY152281A (en) | 4-pyrimidinesulfamide derivative | |
| WO2010091877A3 (en) | Process for producing ambrisentan | |
| WO2010123583A3 (en) | 1-aryl or 1-heteroaryl-pyrido[b]indoles and uses thereof | |
| WO2012042534A3 (en) | Preparation of r-sitagliptin and intermediates thereof | |
| MX352470B (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| MX2017017022A (es) | Metodo para la sintesis de derivados de rapamicina. | |
| JP2013531058A5 (cg-RX-API-DMAC7.html) | ||
| TW201129550A (en) | Method for producing diepoxy compound | |
| MY155300A (en) | Preparation of saturated imidazolinium salts and related compounds | |
| GB201204023D0 (en) | Process for producing V-Coelenterazine compounds | |
| MX2012002818A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| IN2015DN00665A (cg-RX-API-DMAC7.html) | ||
| IL200323A0 (en) | Synthesis of glyt-1 inhibitors | |
| CN103864702B (zh) | 一种在水相中微波催化制备喹唑酮化合物的方法 | |
| WO2012026897A9 (en) | A process for the preparation of imatinib base | |
| GB0508715D0 (en) | Chemical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 JUL 2018 BY COMPUTER PACKAGES INC Effective date: 20151001 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2019 BY RENEWALS TEAM Effective date: 20180614 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2020 BY RENEWALS TEAM Effective date: 20190715 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2021 BY RENEWALS TEAM Effective date: 20200715 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2022 BY IPAN GMBH Effective date: 20210708 |
|
| LAPS | Patent lapsed |